Ciba-Geigy's Italian subsidiary achieved a modest increase for 1991 to 1,063 billion lire ($866.5 million), while profits climbed to 20 billion lire ($16.3 million).
According to Pier Alfonso Borney, director general of Ciba-Geigy Italia, the subsidiary is showing a 3% rise in sales in the early months of 1992, helped by foreign exchange factors. The group's Italian performance reflects in particular a 10% rise in its agricultural division's sales, according to Mr Borney.
Investments trebled last year to 112.3 billion lire, with that figure including work at the new unit at Torre Annunziata which is now 65% complete. Earlier this year, under a joint venture with Chiron of the USA (Marketletter January 1 & 6), the Swiss parent company completed the takeover of the vaccine operations of the Italian Sclavo group.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze